{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:13:38Z","timestamp":1793240018278,"version":"4.5.0"},"reference-count":62,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"678","content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Sci. Transl. Med."],"published-print":{"date-parts":[[2023,1,11]]},"abstract":"<jats:p>\n            Protease inhibitors are among the most powerful antiviral drugs. Nirmatrelvir is the first protease inhibitor specifically developed against the SARS-CoV-2 protease 3CL\n            <jats:sup>pro<\/jats:sup>\n            that has been licensed for clinical use. To identify mutations that confer resistance to this protease inhibitor, we engineered a chimeric vesicular stomatitis virus (VSV) that expressed a polyprotein composed of the VSV glycoprotein (G), the SARS-CoV-2 3CL\n            <jats:sup>pro<\/jats:sup>\n            , and the VSV polymerase (L). Viral replication was thus dependent on the autocatalytic processing of this precursor protein by 3CL\n            <jats:sup>pro<\/jats:sup>\n            and release of the functional viral proteins G and L, and replication of this chimeric VSV was effectively inhibited by nirmatrelvir. Using this system, we applied nirmatrelvir to select for resistance mutations. Resistance was confirmed by retesting nirmatrelvir against the selected mutations in additional VSV-based systems, in an independently developed cellular system, in a biochemical assay, and in a recombinant SARS-CoV-2 system. We demonstrate that some mutants are cross-resistant to ensitrelvir and GC376, whereas others are less resistant to these compounds. Furthermore, we found that most of these resistance mutations already existed in SARS-CoV-2 sequences that have been deposited in the NCBI and GISAID databases, indicating that these mutations were present in circulating SARS-CoV-2 strains.\n          <\/jats:p>","DOI":"10.1126\/scitranslmed.abq7360","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T13:58:07Z","timestamp":1664891887000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":136,"title":["SARS-CoV-2 3CL\n            <sup>pro<\/sup>\n            mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376"],"prefix":"10.1126","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-9490","authenticated-orcid":true,"given":"Emmanuel","family":"Heilmann","sequence":"first","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4556-5967","authenticated-orcid":true,"given":"Francesco","family":"Costacurta","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-8994","authenticated-orcid":true,"given":"Seyed Arad","family":"Moghadasi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-9494","authenticated-orcid":true,"given":"Chengjin","family":"Ye","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78229, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6234-5934","authenticated-orcid":true,"given":"Matteo","family":"Pavan","sequence":"additional","affiliation":[{"name":"Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F.\u00a0Marzolo 5, 35131, Padova, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9057-6297","authenticated-orcid":true,"given":"Davide","family":"Bassani","sequence":"additional","affiliation":[{"name":"Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F.\u00a0Marzolo 5, 35131, Padova, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2805-8215","authenticated-orcid":true,"given":"Andre","family":"Volland","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0183-917X","authenticated-orcid":true,"given":"Claudia","family":"Ascher","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Aging Research, University of Innsbruck, Innsbruck, 6020, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-8630","authenticated-orcid":true,"given":"Alexander Kurt Hermann","family":"Weiss","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Aging Research, University of Innsbruck, Innsbruck, 6020, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5617-8022","authenticated-orcid":true,"given":"David","family":"Bante","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-9112","authenticated-orcid":true,"given":"Reuben S.","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Molecular Biology and Biophysics, Institute for Molecular Virology, University of Minnesota, Minneapolis, MN 55455, USA."},{"name":"Department of Biochemistry and Structural Biology, University of Texas Health San Antonio, San Antonio, TX 78229, USA."},{"name":"Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, TX 78229, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3802","authenticated-orcid":true,"given":"Stefano","family":"Moro","sequence":"additional","affiliation":[{"name":"Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Via F.\u00a0Marzolo 5, 35131, Padova, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-6965","authenticated-orcid":true,"given":"Bernhard","family":"Rupp","sequence":"additional","affiliation":[{"name":"Division of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, 6020, Austria."},{"name":"k.-k. Hofkristallamt, San Diego, CA 92084, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7084-0804","authenticated-orcid":true,"given":"Luis","family":"Martinez-Sobrido","sequence":"additional","affiliation":[{"name":"Texas Biomedical Research Institute, San Antonio, TX 78229, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5825-7237","authenticated-orcid":true,"given":"Dorothee","family":"von Laer","sequence":"additional","affiliation":[{"name":"Institute of Virology, Medical University of Innsbruck, Innsbruck, 6020, Austria."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2012-7"},{"key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jama.2017.10930","article-title":"Combination drug for HCV infection","volume":"318","author":"Voelker R.","year":"2017","unstructured":"R.\u00a0Voelker, Combination drug for HCV infection. JAMA 318, 790 (2017).","journal-title":"JAMA"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02388-6"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M310875200"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.24.13600-13612.2004"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01692-5"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27082561"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.101972"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"S. Iketani H.\u00a0Mohri B.\u00a0Culbertson S.\u00a0J.\u00a0Hong Y.\u00a0Duan M.\u00a0I.\u00a0Luck M.\u00a0K.\u00a0Annavajhala Y.\u00a0Guo Z.\u00a0Sheng A.-C. Uhlemann S.\u00a0P.\u00a0Goff Y.\u00a0Sabo H.\u00a0Yang A.\u00a0Chavez D.\u00a0D.\u00a0Ho Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. bioRxiv 2022.08.07.499047 [ Preprint ] (2022).","DOI":"10.1101\/2022.08.07.499047"},{"key":"e_1_3_3_11_2","doi-asserted-by":"crossref","unstructured":"D. Jochmans C.\u00a0Liu K.\u00a0Donckers A.\u00a0Stoycheva S.\u00a0Boland S.\u00a0K.\u00a0Stevens C.\u00a0De Vita B.\u00a0Vanmechelen P.\u00a0Maes B.\u00a0Tr\u00fceb N.\u00a0Ebert V.\u00a0Thiel S.\u00a0De Jonghe L.\u00a0Vangeel D.\u00a0Bardiot A.\u00a0Jekle L.\u00a0M.\u00a0Blatt L.\u00a0Beigelman J.\u00a0A.\u00a0Symons P.\u00a0Raboisson P.\u00a0Chaltin A.\u00a0Marchand J.\u00a0Neyts J.\u00a0Deval K.\u00a0Vandyck The substitutions L50F E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir. bioRxiv 2022.06.07.495116 [ Preprint ] (2022).","DOI":"10.1101\/2022.06.07.495116"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","unstructured":"S.\u00a0A.\u00a0Moghadasi E.\u00a0Heilmann S.\u00a0N.\u00a0Moraes F.\u00a0L.\u00a0Kearns D.\u00a0von Laer R.\u00a0E.\u00a0Amaro R.\u00a0S.\u00a0Harris Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors. bioRxiv 2022.08.07.503099 [ Preprint ] (2022).","DOI":"10.1101\/2022.08.07.503099"},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","unstructured":"Y. Hu E.\u00a0M.\u00a0Lewandowski H.\u00a0Tan R.\u00a0T.\u00a0Morgan X.\u00a0Zhang L.\u00a0M.\u00a0C. Jacobs S.\u00a0G.\u00a0Butler M.\u00a0V.\u00a0Mongora J.\u00a0Choy Y.\u00a0Chen J.\u00a0Wang Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. bioRxiv 2022.06.28.497978 [ Preprint ] (2022).","DOI":"10.1101\/2022.06.28.497978"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.09.010"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.09.006"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh468"},{"key":"e_1_3_3_17_2","unstructured":"Chemical Computing Group ULC Molecular Operating Environment (MOE) 2022.02 1010 Sherbooke St.\u00a0West Suite #910 Montreal QC Canada H3A 2R7 (2022)."},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-022-03277-0"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1107\/S2052252521001159"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88630-9"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.24.13910"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(92)90216-C"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2017.22.13.30494"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/gch2.1018"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2021.255"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw1065"},{"key":"e_1_3_3_27_2","unstructured":"U.S. Food and Drug Administration Fact sheet for healthcare providers Emergency Use Authorization (EUA) for Paxlovid (2021); www.fda.gov\/media\/143823\/download."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00784-22"},{"key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"e0069722","DOI":"10.1128\/aac.00697-22","article-title":"A randomized phase 2\/3 Study of Ensitrelvir, a novel oral SARS-CoV-2 3C-like PROTEASE INHIBITOR, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part","author":"Mukae H.","year":"2022","unstructured":"H.\u00a0Mukae, H.\u00a0Yotsuyanagi, N.\u00a0Ohmagari, Y.\u00a0Doi, T.\u00a0Imamura, T.\u00a0Sonoyama, T.\u00a0Fukuhara, G.\u00a0Ichihashi, T.\u00a0Sanaki, K.\u00a0Baba, Y.\u00a0Takeda, Y.\u00a0Tsuge, T.\u00a0Uehara, A randomized phase 2\/3 Study of Ensitrelvir, a novel oral SARS-CoV-2 3C-like PROTEASE INHIBITOR, in Japanese patients with mild-to-moderate COVID-19 or asymptomatic SARS-CoV-2 infection: Results of the phase 2a part. Antimicrob. Agents Chemother. ,e0069722 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2111593118"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02168-20"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8754"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-021-00883-2"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1367-5931(00)00206-4"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102863200"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jctc.7b01295"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.5165.1"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2021.1954919"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2021.01.014"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04005-0"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020291"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127377"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2022.128629"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-00689-z"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.1c00684"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl4784"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.0c01457"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M502577200"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1601327113"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.1318"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.70.4.2318-2323.1996"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02701-09"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2006.02.006"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.21"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01863914"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb3405"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomethods\/bpaa014"},{"key":"e_1_3_3_59_2","unstructured":"D.\u00a0A.\u00a0Case T.\u00a0Darden T.\u00a0E.\u00a0Cheatham III C.\u00a0Simmerling J.\u00a0Wang R.\u00a0E.\u00a0Duke R.\u00a0Luo M.\u00a0Crowley R.\u00a0Walker W.\u00a0Zhang K.\u00a0M.\u00a0Merz B.\u00a0Wang S.\u00a0Hayik A.\u00a0Roitberg G.\u00a0Seabra I.\u00a0Kolossv\u00e1ry K.\u00a0F.\u00a0Wong F.\u00a0Paesani J.\u00a0Vanicek X.\u00a0Wu S.\u00a0R.\u00a0Brozell T.\u00a0Steinbrecher H.\u00a0Gohlke L.\u00a0Yang C.\u00a0Tan J.\u00a0Mongan V.\u00a0Hornak G.\u00a0Cui D.\u00a0H.\u00a0Mathews M.\u00a0G.\u00a0Seetin C.\u00a0Sagui V.\u00a0Babin P.\u00a0A.\u00a0Kollman Amber 10: User\u2019s Manual (University of California San\u00a0Francisco 2008)."},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20084"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1021\/ci900508k"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.10126"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.20933"}],"container-title":["Science Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/pdf\/10.1126\/scitranslmed.abq7360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T17:06:26Z","timestamp":1705424786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/scitranslmed.abq7360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":62,"journal-issue":{"issue":"678","published-print":{"date-parts":[[2023,1,11]]}},"alternative-id":["10.1126\/scitranslmed.abq7360"],"URL":"https:\/\/doi.org\/10.1126\/scitranslmed.abq7360","relation":{},"ISSN":["1946-6234","1946-6242"],"issn-type":[{"value":"1946-6234","type":"print"},{"value":"1946-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,11]]},"assertion":[{"value":"2022-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"eabq7360"}}